Jonathan Irish
Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Flow Cytometry | 24 | 2024 | 1075 | 3.200 |
Why?
| Unsupervised Machine Learning | 2 | 2021 | 9 | 1.460 |
Why?
| Single-Cell Analysis | 6 | 2022 | 186 | 1.400 |
Why?
| Germinal Center | 3 | 2022 | 48 | 1.350 |
Why?
| Glioblastoma | 2 | 2023 | 250 | 1.300 |
Why?
| Lymphoma, Follicular | 7 | 2017 | 34 | 1.210 |
Why?
| Leukemia, Myeloid, Acute | 6 | 2023 | 533 | 1.100 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 97 | 1.080 |
Why?
| Mass Spectrometry | 3 | 2019 | 622 | 1.040 |
Why?
| B-Lymphocytes | 4 | 2022 | 762 | 1.020 |
Why?
| Image Cytometry | 2 | 2022 | 5 | 1.000 |
Why?
| Neoplasms | 6 | 2022 | 2086 | 0.990 |
Why?
| Signal Transduction | 18 | 2021 | 4501 | 0.930 |
Why?
| Receptors, Antigen, B-Cell | 5 | 2022 | 107 | 0.920 |
Why?
| Melanoma | 2 | 2021 | 620 | 0.880 |
Why?
| Monocytes | 4 | 2022 | 503 | 0.830 |
Why?
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 56 | 0.770 |
Why?
| Proteomics | 4 | 2022 | 815 | 0.760 |
Why?
| Picornaviridae Infections | 1 | 2021 | 29 | 0.750 |
Why?
| Tumor Microenvironment | 7 | 2023 | 428 | 0.690 |
Why?
| CD40 Antigens | 2 | 2019 | 81 | 0.690 |
Why?
| Cells | 1 | 2020 | 22 | 0.680 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 191 | 0.670 |
Why?
| Education | 1 | 2020 | 93 | 0.660 |
Why?
| Fluorescent Dyes | 1 | 2021 | 298 | 0.650 |
Why?
| CD40 Ligand | 1 | 2019 | 37 | 0.640 |
Why?
| Monitoring, Immunologic | 1 | 2018 | 23 | 0.630 |
Why?
| Nestin | 1 | 2018 | 16 | 0.610 |
Why?
| Phagocytes | 1 | 2019 | 90 | 0.610 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 113 | 0.590 |
Why?
| Immunologic Memory | 2 | 2021 | 313 | 0.590 |
Why?
| Machine Learning | 2 | 2018 | 315 | 0.590 |
Why?
| Phosphorylation | 10 | 2022 | 1558 | 0.570 |
Why?
| Macrophages | 2 | 2023 | 1259 | 0.550 |
Why?
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 111 | 0.550 |
Why?
| Dendritic Cells | 1 | 2019 | 435 | 0.500 |
Why?
| Brain Neoplasms | 1 | 2023 | 966 | 0.500 |
Why?
| Humans | 54 | 2024 | 114043 | 0.460 |
Why?
| Models, Theoretical | 1 | 2018 | 513 | 0.450 |
Why?
| Protein Kinase Inhibitors | 1 | 2018 | 784 | 0.410 |
Why?
| T-Lymphocytes | 2 | 2024 | 1735 | 0.400 |
Why?
| Software | 4 | 2023 | 527 | 0.400 |
Why?
| Lateral Ventricles | 2 | 2023 | 24 | 0.370 |
Why?
| CD8-Positive T-Lymphocytes | 6 | 2022 | 686 | 0.370 |
Why?
| Internet | 3 | 2015 | 591 | 0.360 |
Why?
| Databases as Topic | 1 | 2010 | 63 | 0.350 |
Why?
| Algorithms | 4 | 2021 | 1469 | 0.340 |
Why?
| Lymphocyte Subsets | 1 | 2010 | 79 | 0.340 |
Why?
| Phosphoproteins | 3 | 2016 | 293 | 0.340 |
Why?
| Immunophenotyping | 4 | 2024 | 274 | 0.330 |
Why?
| fms-Like Tyrosine Kinase 3 | 2 | 2006 | 42 | 0.320 |
Why?
| Lymphocytes | 2 | 2023 | 327 | 0.320 |
Why?
| Publishing | 1 | 2010 | 123 | 0.310 |
Why?
| Oximes | 2 | 2018 | 19 | 0.310 |
Why?
| Pyrimidinones | 2 | 2018 | 88 | 0.300 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 1142 | 0.290 |
Why?
| STAT1 Transcription Factor | 3 | 2022 | 63 | 0.290 |
Why?
| MAP Kinase Signaling System | 2 | 2006 | 271 | 0.290 |
Why?
| Leukemia | 2 | 2021 | 208 | 0.290 |
Why?
| Pyridones | 2 | 2018 | 122 | 0.280 |
Why?
| Imidazoles | 2 | 2018 | 203 | 0.280 |
Why?
| Cell Communication | 2 | 2024 | 277 | 0.280 |
Why?
| Cell Transformation, Neoplastic | 2 | 2006 | 307 | 0.270 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2006 | 48 | 0.270 |
Why?
| Cells, Cultured | 8 | 2021 | 3861 | 0.270 |
Why?
| Leukocytes, Mononuclear | 2 | 2022 | 489 | 0.260 |
Why?
| Phenotype | 4 | 2022 | 2784 | 0.260 |
Why?
| T-Lymphocytes, Regulatory | 3 | 2023 | 337 | 0.260 |
Why?
| B-Lymphocyte Subsets | 1 | 2006 | 68 | 0.260 |
Why?
| Tyrosine | 1 | 2006 | 210 | 0.260 |
Why?
| Metabolomics | 2 | 2022 | 511 | 0.250 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 211 | 0.250 |
Why?
| Lymphoma, B-Cell | 1 | 2006 | 87 | 0.250 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 519 | 0.240 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2021 | 959 | 0.230 |
Why?
| Heterozygote | 1 | 2024 | 250 | 0.220 |
Why?
| Forkhead Transcription Factors | 1 | 2024 | 170 | 0.220 |
Why?
| Biomarkers, Tumor | 3 | 2021 | 1032 | 0.210 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2006 | 445 | 0.210 |
Why?
| Extracellular Vesicles | 1 | 2024 | 83 | 0.210 |
Why?
| Cytokines | 4 | 2022 | 1824 | 0.210 |
Why?
| Immunoglobulin G | 2 | 2022 | 766 | 0.200 |
Why?
| Myelodysplastic Syndromes | 1 | 2023 | 119 | 0.200 |
Why?
| HMGB1 Protein | 1 | 2022 | 47 | 0.200 |
Why?
| Mutation | 5 | 2024 | 3338 | 0.200 |
Why?
| CD57 Antigens | 1 | 2021 | 15 | 0.200 |
Why?
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 17 | 0.200 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 124 | 0.190 |
Why?
| Microscopy | 1 | 2023 | 125 | 0.190 |
Why?
| Immunity | 1 | 2022 | 121 | 0.190 |
Why?
| Myositis | 1 | 2022 | 44 | 0.190 |
Why?
| Gene Expression | 1 | 2006 | 1417 | 0.190 |
Why?
| Reproducibility of Results | 3 | 2021 | 2764 | 0.190 |
Why?
| CD4 Antigens | 1 | 2021 | 123 | 0.190 |
Why?
| Rhinovirus | 1 | 2021 | 40 | 0.190 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 845 | 0.190 |
Why?
| Glutaminase | 1 | 2021 | 10 | 0.180 |
Why?
| Palatine Tonsil | 2 | 2018 | 32 | 0.180 |
Why?
| Computational Biology | 2 | 2015 | 528 | 0.180 |
Why?
| Cytomegalovirus | 1 | 2021 | 143 | 0.180 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2022 | 224 | 0.180 |
Why?
| Glucose Transporter Type 1 | 1 | 2021 | 43 | 0.180 |
Why?
| Containment of Biohazards | 1 | 2020 | 11 | 0.180 |
Why?
| CD28 Antigens | 1 | 2020 | 47 | 0.180 |
Why?
| Fas Ligand Protein | 1 | 2020 | 57 | 0.180 |
Why?
| Nephritis | 1 | 2020 | 20 | 0.180 |
Why?
| B7-H1 Antigen | 1 | 2022 | 137 | 0.170 |
Why?
| HLA-DR Antigens | 1 | 2021 | 219 | 0.170 |
Why?
| Graft vs Host Disease | 2 | 2021 | 212 | 0.170 |
Why?
| Anemia, Aplastic | 1 | 2020 | 30 | 0.170 |
Why?
| Lung Neoplasms | 2 | 2023 | 2159 | 0.170 |
Why?
| Automation | 1 | 2020 | 74 | 0.170 |
Why?
| Cytomegalovirus Infections | 1 | 2021 | 180 | 0.170 |
Why?
| Biological Products | 1 | 2022 | 166 | 0.170 |
Why?
| Interleukin-2 | 1 | 2020 | 413 | 0.160 |
Why?
| Adenoids | 1 | 2018 | 10 | 0.160 |
Why?
| STAT5 Transcription Factor | 3 | 2021 | 44 | 0.160 |
Why?
| Antibodies, Viral | 1 | 2022 | 520 | 0.160 |
Why?
| RNA, Viral | 1 | 2022 | 565 | 0.160 |
Why?
| Dexamethasone | 1 | 2021 | 316 | 0.160 |
Why?
| Tuberous Sclerosis | 1 | 2019 | 36 | 0.160 |
Why?
| Young Adult | 4 | 2021 | 10444 | 0.150 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 97 | 0.150 |
Why?
| Antibodies, Neoplasm | 1 | 2018 | 30 | 0.150 |
Why?
| Adult | 7 | 2021 | 30375 | 0.150 |
Why?
| Carcinoma, Renal Cell | 1 | 2020 | 168 | 0.150 |
Why?
| MAP Kinase Kinase Kinases | 1 | 2018 | 68 | 0.150 |
Why?
| Astrocytoma | 1 | 2019 | 106 | 0.150 |
Why?
| Sensitivity and Specificity | 2 | 2022 | 1690 | 0.150 |
Why?
| Neural Stem Cells | 1 | 2019 | 113 | 0.150 |
Why?
| Carcinogenesis | 1 | 2019 | 175 | 0.140 |
Why?
| Aged | 6 | 2021 | 18969 | 0.140 |
Why?
| Proteins | 2 | 2019 | 906 | 0.140 |
Why?
| Lymphocyte Activation | 1 | 2021 | 1036 | 0.140 |
Why?
| Adenocarcinoma | 1 | 2023 | 787 | 0.140 |
Why?
| Immunoglobulin M | 3 | 2022 | 245 | 0.140 |
Why?
| Middle Aged | 7 | 2021 | 26605 | 0.140 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 641 | 0.140 |
Why?
| Neutrophils | 1 | 2022 | 1089 | 0.140 |
Why?
| Hematologic Neoplasms | 1 | 2018 | 136 | 0.140 |
Why?
| Lymphoma, Mantle-Cell | 1 | 2016 | 18 | 0.140 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.140 |
Why?
| Receptors, Immunologic | 1 | 2017 | 198 | 0.130 |
Why?
| Kidney Neoplasms | 1 | 2020 | 324 | 0.130 |
Why?
| Animals | 12 | 2024 | 31565 | 0.130 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 56 | 0.130 |
Why?
| Sepsis | 1 | 2022 | 507 | 0.130 |
Why?
| Female | 13 | 2024 | 59325 | 0.130 |
Why?
| Male | 12 | 2024 | 55396 | 0.130 |
Why?
| Pilot Projects | 1 | 2020 | 1360 | 0.130 |
Why?
| Cell Line | 1 | 2021 | 2629 | 0.130 |
Why?
| Cell Line, Tumor | 2 | 2021 | 2698 | 0.120 |
Why?
| Antineoplastic Agents | 2 | 2022 | 1875 | 0.120 |
Why?
| Precision Medicine | 1 | 2019 | 335 | 0.120 |
Why?
| NF-kappa B | 1 | 2019 | 636 | 0.120 |
Why?
| Antigen-Presenting Cells | 1 | 2015 | 150 | 0.120 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 660 | 0.110 |
Why?
| Information Dissemination | 2 | 2020 | 185 | 0.110 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2017 | 615 | 0.110 |
Why?
| Clonal Evolution | 1 | 2013 | 25 | 0.100 |
Why?
| Syk Kinase | 2 | 2016 | 18 | 0.100 |
Why?
| Hypertension, Pulmonary | 1 | 2023 | 1736 | 0.100 |
Why?
| DNA, Neoplasm | 1 | 2013 | 155 | 0.100 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2016 | 145 | 0.100 |
Why?
| Mitogen-Activated Protein Kinase 1 | 2 | 2016 | 164 | 0.090 |
Why?
| Apoptosis | 1 | 2020 | 2349 | 0.090 |
Why?
| Neoplastic Stem Cells | 1 | 2015 | 327 | 0.090 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2013 | 193 | 0.090 |
Why?
| Biomarkers | 4 | 2022 | 3397 | 0.090 |
Why?
| DNA Damage | 2 | 2018 | 351 | 0.090 |
Why?
| Prognosis | 2 | 2010 | 3315 | 0.090 |
Why?
| CD79 Antigens | 2 | 2022 | 16 | 0.090 |
Why?
| Phosphoprotein Phosphatases | 1 | 2010 | 64 | 0.090 |
Why?
| Models, Immunological | 1 | 2010 | 90 | 0.090 |
Why?
| Extracellular Space | 1 | 2010 | 116 | 0.080 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2009 | 18 | 0.080 |
Why?
| Glycolysis | 2 | 2021 | 224 | 0.080 |
Why?
| Disease Progression | 3 | 2013 | 2371 | 0.080 |
Why?
| Mice | 6 | 2022 | 14841 | 0.080 |
Why?
| Lymphocyte Depletion | 1 | 2009 | 115 | 0.080 |
Why?
| Protein-Tyrosine Kinases | 2 | 2016 | 393 | 0.080 |
Why?
| Transplantation, Homologous | 2 | 2021 | 377 | 0.080 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2008 | 3 | 0.080 |
Why?
| Myeloproliferative Disorders | 1 | 2008 | 26 | 0.080 |
Why?
| Enzyme Activation | 1 | 2010 | 771 | 0.080 |
Why?
| Drug Evaluation, Preclinical | 1 | 2009 | 159 | 0.080 |
Why?
| Lymphoma | 1 | 2009 | 176 | 0.080 |
Why?
| Asthma | 1 | 2021 | 2021 | 0.080 |
Why?
| Disease | 1 | 2009 | 85 | 0.070 |
Why?
| Cooperative Behavior | 1 | 2010 | 376 | 0.070 |
Why?
| Immunologic Factors | 1 | 2009 | 217 | 0.070 |
Why?
| Bayes Theorem | 1 | 2009 | 327 | 0.070 |
Why?
| Survival Analysis | 1 | 2010 | 1206 | 0.070 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 99 | 0.070 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1519 | 0.070 |
Why?
| Peptide Mapping | 1 | 2006 | 60 | 0.070 |
Why?
| Adolescent | 2 | 2021 | 17800 | 0.070 |
Why?
| Cluster Analysis | 2 | 2020 | 452 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2021 | 1947 | 0.060 |
Why?
| Protein Isoforms | 1 | 2006 | 337 | 0.060 |
Why?
| Diagnosis, Differential | 2 | 2022 | 1331 | 0.060 |
Why?
| Hydrogen Peroxide | 1 | 2006 | 288 | 0.060 |
Why?
| Carcinogens, Environmental | 1 | 2004 | 7 | 0.060 |
Why?
| Case-Control Studies | 2 | 2022 | 3003 | 0.060 |
Why?
| Haploinsufficiency | 1 | 2024 | 42 | 0.060 |
Why?
| Lymphopenia | 1 | 2024 | 49 | 0.060 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 388 | 0.060 |
Why?
| ras Proteins | 1 | 2004 | 138 | 0.050 |
Why?
| Fluorescent Antibody Technique | 1 | 2004 | 396 | 0.050 |
Why?
| Thymus Gland | 1 | 2024 | 296 | 0.050 |
Why?
| Lipid Bilayers | 1 | 2024 | 94 | 0.050 |
Why?
| Antibodies, Monoclonal | 1 | 2009 | 1257 | 0.050 |
Why?
| Kinetics | 1 | 2006 | 1547 | 0.050 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 191 | 0.050 |
Why?
| Epoprostenol | 1 | 2023 | 133 | 0.050 |
Why?
| Calreticulin | 1 | 2022 | 24 | 0.050 |
Why?
| Gain of Function Mutation | 1 | 2022 | 30 | 0.050 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 224 | 0.050 |
Why?
| Mammals | 1 | 2024 | 241 | 0.050 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2023 | 197 | 0.050 |
Why?
| HEK293 Cells | 1 | 2024 | 590 | 0.050 |
Why?
| Cell Count | 1 | 2022 | 303 | 0.050 |
Why?
| Trans-Activators | 1 | 2004 | 366 | 0.050 |
Why?
| Receptors, IgG | 1 | 2022 | 67 | 0.050 |
Why?
| Janus Kinase 1 | 1 | 2021 | 23 | 0.050 |
Why?
| Alternaria | 1 | 2021 | 8 | 0.050 |
Why?
| Calgranulin B | 1 | 2021 | 7 | 0.050 |
Why?
| Pyroglyphidae | 1 | 2021 | 17 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2015 | 990 | 0.050 |
Why?
| Cell Death | 1 | 2022 | 322 | 0.050 |
Why?
| Proto-Oncogene Proteins | 1 | 2004 | 607 | 0.050 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 4680 | 0.040 |
Why?
| Th17 Cells | 1 | 2021 | 58 | 0.040 |
Why?
| Computer Simulation | 2 | 2015 | 873 | 0.040 |
Why?
| Tretinoin | 1 | 2021 | 122 | 0.040 |
Why?
| Listeriosis | 1 | 2021 | 61 | 0.040 |
Why?
| Glutamine | 1 | 2021 | 91 | 0.040 |
Why?
| Interleukin-7 | 1 | 2020 | 45 | 0.040 |
Why?
| Immune System Diseases | 1 | 2020 | 32 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2021 | 148 | 0.040 |
Why?
| Drug Synergism | 1 | 2021 | 315 | 0.040 |
Why?
| Oxidative Phosphorylation | 1 | 2021 | 154 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2022 | 428 | 0.040 |
Why?
| Healthy Volunteers | 1 | 2021 | 191 | 0.040 |
Why?
| Cell Nucleus | 1 | 2023 | 552 | 0.040 |
Why?
| Listeria monocytogenes | 1 | 2021 | 111 | 0.040 |
Why?
| Th2 Cells | 1 | 2021 | 154 | 0.040 |
Why?
| Inventions | 1 | 2019 | 17 | 0.040 |
Why?
| Mice, SCID | 1 | 2020 | 312 | 0.040 |
Why?
| Tissue Donors | 1 | 2021 | 314 | 0.040 |
Why?
| Linear Models | 1 | 2022 | 768 | 0.040 |
Why?
| Fluorescence | 1 | 2019 | 148 | 0.040 |
Why?
| Thyroid Nuclear Factor 1 | 1 | 2019 | 14 | 0.040 |
Why?
| Cell Proliferation | 2 | 2021 | 2173 | 0.040 |
Why?
| Image Processing, Computer-Assisted | 1 | 2023 | 684 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2023 | 1624 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 552 | 0.040 |
Why?
| Interleukin-6 | 1 | 2022 | 673 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 580 | 0.040 |
Why?
| Immune Tolerance | 1 | 2020 | 321 | 0.040 |
Why?
| National Institutes of Health (U.S.) | 1 | 2018 | 105 | 0.040 |
Why?
| Cell Extracts | 1 | 2018 | 15 | 0.040 |
Why?
| Streptomyces | 1 | 2018 | 10 | 0.040 |
Why?
| Recurrence | 2 | 2013 | 925 | 0.040 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 84 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2019 | 241 | 0.040 |
Why?
| Histones | 1 | 2022 | 529 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2004 | 1311 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2019 | 316 | 0.030 |
Why?
| Phospholipase C gamma | 1 | 2016 | 26 | 0.030 |
Why?
| Bone Marrow | 1 | 2018 | 243 | 0.030 |
Why?
| src-Family Kinases | 1 | 2016 | 88 | 0.030 |
Why?
| Consensus | 1 | 2018 | 532 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2018 | 345 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 249 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1356 | 0.030 |
Why?
| Stem Cells | 1 | 2019 | 541 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2017 | 383 | 0.030 |
Why?
| Glucose | 1 | 2020 | 899 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2019 | 926 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2022 | 2384 | 0.030 |
Why?
| CREB-Binding Protein | 1 | 2015 | 27 | 0.030 |
Why?
| Database Management Systems | 1 | 2015 | 47 | 0.030 |
Why?
| Mitochondria | 1 | 2020 | 744 | 0.030 |
Why?
| Metabolome | 1 | 2018 | 274 | 0.030 |
Why?
| Biomedical Research | 1 | 2020 | 582 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 397 | 0.030 |
Why?
| Cytoplasm | 1 | 2015 | 255 | 0.030 |
Why?
| Autoantibodies | 1 | 2022 | 1347 | 0.030 |
Why?
| Cell Differentiation | 1 | 2021 | 1695 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2022 | 2537 | 0.030 |
Why?
| Infant, Newborn | 1 | 2024 | 5038 | 0.030 |
Why?
| Histocompatibility Antigens Class II | 1 | 2015 | 350 | 0.030 |
Why?
| Histiocytes | 1 | 2013 | 6 | 0.030 |
Why?
| Mutation Rate | 1 | 2013 | 24 | 0.030 |
Why?
| E-Selectin | 1 | 2013 | 52 | 0.030 |
Why?
| Leukocyte Common Antigens | 1 | 2013 | 75 | 0.030 |
Why?
| Chronic Disease | 1 | 2018 | 1577 | 0.030 |
Why?
| Clone Cells | 1 | 2013 | 247 | 0.030 |
Why?
| Interleukin-4 | 1 | 2013 | 204 | 0.020 |
Why?
| Blood Glucose | 1 | 2021 | 1827 | 0.020 |
Why?
| Exome | 1 | 2013 | 200 | 0.020 |
Why?
| Cell Separation | 1 | 2013 | 290 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2021 | 3498 | 0.020 |
Why?
| Gene Frequency | 1 | 2013 | 476 | 0.020 |
Why?
| Chromatin | 1 | 2015 | 424 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2020 | 2321 | 0.020 |
Why?
| Child | 3 | 2019 | 18400 | 0.020 |
Why?
| Interleukins | 1 | 2013 | 236 | 0.020 |
Why?
| Interleukin-10 | 1 | 2013 | 293 | 0.020 |
Why?
| Genome, Human | 1 | 2013 | 347 | 0.020 |
Why?
| Databases, Factual | 1 | 2015 | 1125 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2021 | 6306 | 0.020 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 437 | 0.020 |
Why?
| Immunization, Passive | 1 | 2009 | 73 | 0.020 |
Why?
| U937 Cells | 1 | 2009 | 22 | 0.020 |
Why?
| Janus Kinase 2 | 1 | 2008 | 31 | 0.020 |
Why?
| Lung | 1 | 2021 | 3521 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 4595 | 0.020 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 140 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 6195 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 318 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2009 | 695 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2009 | 1144 | 0.020 |
Why?
| Killer Cells, Natural | 1 | 2009 | 380 | 0.020 |
Why?
| Child, Preschool | 1 | 2019 | 9114 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2008 | 1162 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1836 | 0.010 |
Why?
| Intracellular Fluid | 1 | 2004 | 27 | 0.010 |
Why?
| Membrane Proteins | 1 | 2009 | 1016 | 0.010 |
Why?
| United States | 1 | 2018 | 12137 | 0.010 |
Why?
| Antigens | 1 | 2004 | 317 | 0.010 |
Why?
| Models, Biological | 1 | 2009 | 1611 | 0.010 |
Why?
| Treatment Outcome | 1 | 2008 | 9049 | 0.010 |
Why?
|
|
Irish's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|